Marimastat

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.[1][2]

Marimastat
Clinical data
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • Development terminated?
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H29N3O5
Molar mass331.408 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Marimastat performed poorly in clinical trials,[3] and development was terminated.

See also

References

  1. "Marimastat". National Cancer Institute.
  2. Millar, AW; Brown PD; Moore J; et al. (1998). "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". Br J Clin Pharmacol. 45 (1): 21–6. doi:10.1046/j.1365-2125.1998.00639.x. PMC 1873993. PMID 9489589.
  3. Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol. 22 (23): 4683–90. doi:10.1200/JCO.2004.08.054. PMID 15570070.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.